Find Funding Opportunities

Returning 1217 results

Center without Walls for PET Ligand Development for Alzheimer's disease related dementias (ADRDs) (U19 Clinical Trial Optional)

RFA
Friday, March 2, 2018
Wednesday, May 9, 2018
U19
RFA-NS-18-025

Funding Opportunity Purpose

This funding opportunity announcement(FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for improvement of ligand specificity and selectivity, initial screening of ligands in appropriated animal models, and radioligand formulation and first-in-human testing. Applications must include an administrative core, a medicinal chemistry core, a clincial core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

Pathway and Target Identification for Alzhiemers Disease Related Dementias (ADRDs) (U01 Clinical Trial Not Allowed)

PAR
Wednesday, February 14, 2018
Tuesday, April 17, 2018
U01
PAR-18-661

Funding Opportunity Purpose

The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.

Administrative Supplement for Research on Sex/Gender Influences (Admin Supp - Clinical Trial Optional)

PA
Tuesday, February 13, 2018
Tuesday, March 27, 2018
333
PA-18-658

Funding Opportunity Purpose

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.

Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed)

RFA
Friday, February 9, 2018
Tuesday, May 1, 2018
U54
RFA-NS-18-024

Funding Opportunity Purpose

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

Opportunities for Collaborative Research at the NIH Clinical Center (U01 - Clinical Trial Optional)

PAR
Thursday, February 8, 2018
Thursday, April 12, 2018
U01
PAR-18-646

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (U01 Clinical Trial Not Allowed)

RFA
Wednesday, February 7, 2018
Tuesday, May 1, 2018
U01
RFA-NS-18-015

Funding Opportunity Purpose

The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

PAR
Monday, January 29, 2018
Clinical Trials Research
Wednesday, April 18, 2018
R01
PAR-18-596

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease. Further information on the specific topics of interest will be announced through a series of notices published in late January and early February of 2018.

Limited Competition: Clinical Research Sites for MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01-Clinical Trials Not Allowed)

RFA
Friday, December 22, 2017
Thursday, May 3, 2018
U01
RFA-HL-19-008

Funding Opportunity Purpose

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to advance knowledge of the HIV infection, with a focus on HIV-related comorbidities by supporting current Clinical Research Sites (CRS) of the Multi-Center AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). Through this FOA each CRS will implement the full MACS/WIHS-CCS unified science agenda and provide expertise to lead part of the unified science agenda (e.g., protocol development, as a reading center, or laboratory). Targeted recruitment will be supported with justification. A companion cooperative agreement will support the MACS/WIHS-CCS Data Analysis and Coordination Center (DACC).

Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01 Clinical Trials Not Allowed)

RFA
Friday, December 22, 2017
Thursday, May 3, 2018
U01
RFA-HL-19-007

Funding Opportunity Purpose

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to support a Data Analysis and Coordination Center (DACC) for the Multicenter AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). The DACC will work as a member of the MACS/WIHS-CCS consortium to advance knowledge of basic and clinical science, and the epidemiology of HIV infection in the US, with a focus on HIV-related comorbidities. A companion cooperative agreement will support MACS/WIHS-CCS Clinical Research Sites (CRS)

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)

PA
Tuesday, December 19, 2017
Tuesday, March 6, 2018
333
PA-18-517

Funding Opportunity Purpose

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

Pages